NEWS & EVENTS
PRESS RELEASES 2007
ELUSYS’ ANTHRAX THERAPEUTIC, ANTHIM™, SELECTED TO “100 GREAT INVESTIGATIONAL DRUGS” LIST BY R&D DIRECTIONS
Pine Brook, NJ – April 20, 2007 – Elusys Therapeutics, Inc., a biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections, today announced that Anthim™, the company’s anthrax antibody therapeutic, has been selected to R&D Directions’ list of “100 Great Investigational Drugs.” For a product to be selected to this independent list, it must show substantial potential in a major or growing therapeutic area and be under active development.
Elizabeth Posillico, Ph.D., President and CEO of Elusys Therapeutics, commented on the announcement, “This is a real honor and we are delighted that Anthim is counted among the 100 Great Investigational Drugs. I speak for our entire company when I say we are proud to have developed a product that can protect and save American lives.”
George Elston, Vice President of Finance & Government Affairs commented, “Anthim has demonstrated impressive clinical safety and efficacy and can be rapidly administered intramuscularly in an emergency situation. A single dose of Anthim significantly increases survival and this drug can be given either before or after anthrax exposure. Anthim is expected to be equally effective against antibiotic resistant strains of anthrax and is an important treatment for this deadly biowarfare agent.”
Please visit www.elusys.com to view a reprint of R&D Directions’ 100 Great Investigational Drugs.
Anthim™ Background
Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax, blocking the bacteria’s ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats.
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life-threatening infectious disease. Current investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.
Contact:
Bryan P. Murphy
LaVoie Group
978.745.4200 X 105
bmurphy@lavoiegroup.com